233 related articles for article (PubMed ID: 18563956)
1. Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia.
Boulton DW; Kollia G; Mallikaarjun S; Komoroski B; Sharma A; Kovalick LJ; Reeves RA
Clin Pharmacokinet; 2008; 47(7):475-85. PubMed ID: 18563956
[TBL] [Abstract][Full Text] [Related]
2. Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia.
Turncliff R; Hard M; Du Y; Risinger R; Ehrich EW
Schizophr Res; 2014 Nov; 159(2-3):404-10. PubMed ID: 25266547
[TBL] [Abstract][Full Text] [Related]
3. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R
Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
Daniel DG; Currier GW; Zimbroff DL; Allen MH; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT
J Psychiatr Pract; 2007 May; 13(3):170-7. PubMed ID: 17522560
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study.
Mallikaarjun S; Kane JM; Bricmont P; McQuade R; Carson W; Sanchez R; Forbes RA; Fleischhacker WW
Schizophr Res; 2013 Oct; 150(1):281-8. PubMed ID: 23890595
[TBL] [Abstract][Full Text] [Related]
7. A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder.
Harlin M; Yildirim M; Such P; Madera-McDonough J; Jan M; Jin N; Watkin S; Larsen F
CNS Drugs; 2023 Apr; 37(4):337-350. PubMed ID: 36961650
[TBL] [Abstract][Full Text] [Related]
8. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study.
Findling RL; Kauffman RE; Sallee FR; Carson WH; Nyilas M; Mallikaarjun S; Shoaf SE; Forbes RA; Boulton DW; Pikalov A
J Clin Psychopharmacol; 2008 Aug; 28(4):441-6. PubMed ID: 18626272
[TBL] [Abstract][Full Text] [Related]
9. Intramuscular aripiprazole in the control of agitation.
Currier GW; Citrome LL; Zimbroff DL; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT
J Psychiatr Pract; 2007 May; 13(3):159-69. PubMed ID: 17522559
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
Weiden PJ; Du Y; von Moltke L; Wehr A; Hard M; Marandi M; Walling DP
CNS Drugs; 2020 Sep; 34(9):961-972. PubMed ID: 32621071
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of the PLACID study: a randomised trial comparing the efficacy and safety of inhaled loxapine versus IM aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder.
San L; Estrada G; Oudovenko N; Vieta E
BMC Psychiatry; 2017 Apr; 17(1):126. PubMed ID: 28376877
[TBL] [Abstract][Full Text] [Related]
12. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study.
Andrezina R; Marcus RN; Oren DA; Manos G; Stock E; Carson WH; McQuade RD
Curr Med Res Opin; 2006 Nov; 22(11):2209-19. PubMed ID: 17076982
[TBL] [Abstract][Full Text] [Related]
13. Intramuscular aripiprazole in the acute management of psychomotor agitation.
De Filippis S; Cuomo I; Lionetto L; Janiri D; Simmaco M; Caloro M; De Persis S; Piazzi G; Simonetti A; Telesforo CL; Sciarretta A; Caccia F; Gentile G; Kotzalidis GD; Girardi P
Pharmacotherapy; 2013 Jun; 33(6):603-14. PubMed ID: 23505124
[TBL] [Abstract][Full Text] [Related]
14. Initiation of aripiprazole once-monthly in patients with schizophrenia.
Raoufinia A; Baker RA; Eramo A; Nylander AG; Landsberg W; Kostic D; Larsen F
Curr Med Res Opin; 2015 Mar; 31(3):583-92. PubMed ID: 25586294
[TBL] [Abstract][Full Text] [Related]
15. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole.
Zimbroff DL; Marcus RN; Manos G; Stock E; McQuade RD; Auby P; Oren DA
J Clin Psychopharmacol; 2007 Apr; 27(2):171-6. PubMed ID: 17414241
[TBL] [Abstract][Full Text] [Related]
16. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
Mallikaarjun S; Shoaf SE; Boulton DW; Bramer SL
Clin Pharmacokinet; 2008; 47(8):533-42. PubMed ID: 18611062
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers.
Mallikaarjun S; Salazar DE; Bramer SL
J Clin Pharmacol; 2004 Feb; 44(2):179-87. PubMed ID: 14747427
[TBL] [Abstract][Full Text] [Related]
18. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
Andrezina R; Josiassen RC; Marcus RN; Oren DA; Manos G; Stock E; Carson WH; Iwamoto T
Psychopharmacology (Berl); 2006 Oct; 188(3):281-92. PubMed ID: 16953381
[TBL] [Abstract][Full Text] [Related]
19. Aripiprazole.
Winans E
Am J Health Syst Pharm; 2003 Dec; 60(23):2437-45. PubMed ID: 14686220
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial.
Tran-Johnson TK; Sack DA; Marcus RN; Auby P; McQuade RD; Oren DA
J Clin Psychiatry; 2007 Jan; 68(1):111-9. PubMed ID: 17284138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]